SCHEMBL3013290

SCHEMBL3013290

COc1ccc(Cl)cc1S(=O)(=O)C1CCN(c2nc(-c3cc(C)ccc3C)cs2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 4/20 0.51
RAB9A P51151 5/20 0.40
SMN1; SMN2 Q16637 5/20 0.40
MAPT P10636 3/20 0.40
NPC1 O15118 2/20 0.40
MAPK1 P28482 3/20 0.39
TP53 P04637 1/20 0.38
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 2/20 0.38
POLB P06746 2/20 0.38
HPGD P15428 2/20 0.38
HTT P42858 2/20 0.37
GAA P10253 1/20 0.37
TSHR P16473 2/20 0.36
REV1 Q9UBZ9 1/20 0.36
NPSR1 Q6W5P4 2/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014461 0.90 AR (0.52) ARRAB9ASMN1; SMN2MAPTNPC1
SCHEMBL3020564 0.90 ALPL (0.42) ARRAB9ASMN1; SMN2MAPTNPC1
SCHEMBL3010971 0.90 AR (0.51) ARRAB9ASMN1; SMN2MAPTNPC1
SCHEMBL3015954 0.89 AR (0.54) ARRAB9ASMN1; SMN2MAPTNPC1
SCHEMBL2997805 0.89 SMN1; SMN2 (0.52) RAB9ASMN1; SMN2MAPTNPC1MAPK1
SCHEMBL3017129 0.88 RAB9A (0.40) ARRAB9ASMN1; SMN2MAPTNPC1
SCHEMBL3010499 0.88 AR (0.54) ARRAB9ASMN1; SMN2MAPTNPC1
SCHEMBL3022225 0.88 AR (0.53) ARRAB9ASMN1; SMN2MAPTNPC1
SCHEMBL3003825 0.87 SMN1; SMN2 (0.42) ARRAB9ASMN1; SMN2MAPTNPC1
SCHEMBL3016836 0.87 SMN1; SMN2 (0.47) RAB9ASMN1; SMN2MAPTNPC1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885RAB9A 2943/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.